Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack Ansell

Showing results (21-30 of 120) with videos related to

Pageof 12
Sort By:
Best Practice & Research. Clinical Haematology|August 20, 2013
Disadvantages of VKA and requirements for novel anticoagulantsRaji Shameem, Jack Ansell
Thrombosis and Haemostasis|June 29, 2012
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillationSimon Mantha, Jack Ansell
Drugs|December 14, 2004
Current options in the prevention of thromboembolic diseaseJack Ansell, David Bergqvist
Discovery Medicine|December 31, 2009
Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?Jennifer Zikria, Jack Ansell
Journal of Thrombosis and Thrombolysis|April 19, 2013
Target specific oral anticoagulants in the management of thromboembolic disease in the elderlySurekha Maddula, Jack Ansell
Journal of Thrombosis and Thrombolysis|July 4, 2014
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolismSimon Mantha, Jack Ansell
Current Drug Discovery Technologies|August 16, 2011
New targets for anticoagulation and future perspectivesJack Ansell, David Askin
Drugs|January 27, 2005
Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolismElizabeth Blanchard, Jack Ansell
The Journal of Supportive Oncology|September 1, 2004
Management of thrombosis in the cancer patientNancy Andrea, Jack Ansell
Expert Opinion on Investigational Drugs|November 18, 2008
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdictJennifer Carreiro, Jack Ansell
Pageof 12

Showing results (21-30 of 120) with videos related to

Sort By:
Pageof 12
Best Practice & Research. Clinical Haematology|August 20, 2013
Disadvantages of VKA and requirements for novel anticoagulantsRaji Shameem, Jack Ansell
Thrombosis and Haemostasis|June 29, 2012
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillationSimon Mantha, Jack Ansell
Drugs|December 14, 2004
Current options in the prevention of thromboembolic diseaseJack Ansell, David Bergqvist
Discovery Medicine|December 31, 2009
Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?Jennifer Zikria, Jack Ansell
Journal of Thrombosis and Thrombolysis|April 19, 2013
Target specific oral anticoagulants in the management of thromboembolic disease in the elderlySurekha Maddula, Jack Ansell
Journal of Thrombosis and Thrombolysis|July 4, 2014
Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolismSimon Mantha, Jack Ansell
Current Drug Discovery Technologies|August 16, 2011
New targets for anticoagulation and future perspectivesJack Ansell, David Askin
Drugs|January 27, 2005
Extended anticoagulation therapy for the primary and secondary prevention of venous thromboembolismElizabeth Blanchard, Jack Ansell
The Journal of Supportive Oncology|September 1, 2004
Management of thrombosis in the cancer patientNancy Andrea, Jack Ansell
Expert Opinion on Investigational Drugs|November 18, 2008
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdictJennifer Carreiro, Jack Ansell
Pageof 12